Leerink Partnrs Brokers Decrease Earnings Estimates for ELDN

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Research analysts at Leerink Partnrs lowered their Q4 2024 earnings per share (EPS) estimates for shares of Eledon Pharmaceuticals in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings per share of ($0.32) for the quarter, down from their prior forecast of ($0.16). The consensus estimate for Eledon Pharmaceuticals' current full-year earnings is ($0.81) per share. Leerink Partnrs also issued estimates for Eledon Pharmaceuticals' FY2025 earnings at ($1.02) EPS, FY2026 earnings at ($0.99) EPS, FY2027 earnings at ($1.23) EPS and FY2028 earnings at ($1.20) EPS.

Other research analysts also recently issued research reports about the company. Guggenheim initiated coverage on Eledon Pharmaceuticals in a report on Tuesday, January 28th. They set a "buy" rating and a $9.00 target price on the stock. HC Wainwright reissued a "buy" rating and issued a $16.00 price target on shares of Eledon Pharmaceuticals in a report on Wednesday, November 20th.

Eledon Pharmaceuticals Stock Down 0.2 %

NASDAQ:ELDN traded down $0.01 during trading hours on Monday, reaching $4.49. 123,413 shares of the stock were exchanged, compared to its average volume of 299,080. The firm has a 50 day simple moving average of $4.39 and a 200-day simple moving average of $3.64. Eledon Pharmaceuticals has a 52 week low of $1.52 and a 52 week high of $5.54. The stock has a market capitalization of $268.23 million, a P/E ratio of -2.23 and a beta of 0.79.

Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last released its earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.02).

Institutional Trading of Eledon Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Inspire Investing LLC bought a new stake in shares of Eledon Pharmaceuticals in the 4th quarter worth approximately $802,000. Geode Capital Management LLC raised its stake in Eledon Pharmaceuticals by 9.7% during the 3rd quarter. Geode Capital Management LLC now owns 378,058 shares of the company's stock valued at $942,000 after acquiring an additional 33,569 shares in the last quarter. Dimensional Fund Advisors LP bought a new stake in Eledon Pharmaceuticals during the 2nd quarter valued at $80,000. Clarity Capital Partners LLC bought a new stake in Eledon Pharmaceuticals during the 3rd quarter valued at $29,000. Finally, Kera Capital Partners Inc. bought a new stake in Eledon Pharmaceuticals during the 4th quarter valued at $106,000. Institutional investors own 56.77% of the company's stock.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).